Liaoning Chengda Biotechnology Co., Ltd. (SHA:688739)
21.02
+0.47 (2.29%)
At close: Sep 30, 2026
SHA:688739 Revenue
Liaoning Chengda Biotechnology had revenue of 403.92M CNY in the quarter ending June 30, 2026, with 15.94% growth. This brings the company's revenue in the last twelve months to 1.36B, down -9.42% year-over-year. In the year 2025, Liaoning Chengda Biotechnology had annual revenue of 1.39B, down -17.06%.
Revenue (ttm)
1.36B
Revenue Growth
-9.42%
P/S Ratio
6.35
Revenue / Employee
858.53K
Employees
1,585
Market Cap
8.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | -285.95M | -17.06% |
| Dec 31, 2024 | 1.68B | -73.86M | -4.22% |
| Dec 31, 2023 | 1.75B | -64.90M | -3.58% |
| Dec 31, 2022 | 1.81B | -273.04M | -13.08% |
| Dec 31, 2021 | 2.09B | 92.47M | 4.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Novogene | 2.28B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Aurisco Pharmaceutical | 1.70B |
| Vcanbio Cell & Gene Engineering Corp., | 1.40B |
| Chengdu Easton Biopharmaceuticals | 1.34B |
| Bio-Thera Solutions | 1.01B |
| Daan Gene | 746.91M |